These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 29426770)

  • 1. Diastereoselective synthesis of fused cyclopropyl-3-amino-2,4-oxazine β-amyloid cleaving enzyme (BACE) inhibitors and their biological evaluation.
    Low JD; Bartberger MD; Cheng Y; Whittington D; Xue Q; Wood S; Allen JR; Minatti AE
    Bioorg Med Chem Lett; 2018 Apr; 28(6):1111-1115. PubMed ID: 29426770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spirocyclic sulfamides as β-secretase 1 (BACE-1) inhibitors for the treatment of Alzheimer's disease: utilization of structure based drug design, WaterMap, and CNS penetration studies to identify centrally efficacious inhibitors.
    Brodney MA; Barreiro G; Ogilvie K; Hajos-Korcsok E; Murray J; Vajdos F; Ambroise C; Christoffersen C; Fisher K; Lanyon L; Liu J; Nolan CE; Withka JM; Borzilleri KA; Efremov I; Oborski CE; Varghese A; O'Neill BT
    J Med Chem; 2012 Nov; 55(21):9224-39. PubMed ID: 22984865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of amino-1,4-oxazines as potent BACE-1 inhibitors.
    Veenstra SJ; Rueeger H; Voegtle M; Lueoend R; Holzer P; Hurth K; Tintelnot-Blomley M; Frederiksen M; Rondeau JM; Jacobson L; Staufenbiel M; Neumann U; Machauer R
    Bioorg Med Chem Lett; 2018 Jul; 28(12):2195-2200. PubMed ID: 29764741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From fragment screening to in vivo efficacy: optimization of a series of 2-aminoquinolines as potent inhibitors of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1).
    Cheng Y; Judd TC; Bartberger MD; Brown J; Chen K; Fremeau RT; Hickman D; Hitchcock SA; Jordan B; Li V; Lopez P; Louie SW; Luo Y; Michelsen K; Nixey T; Powers TS; Rattan C; Sickmier EA; St Jean DJ; Wahl RC; Wen PH; Wood S
    J Med Chem; 2011 Aug; 54(16):5836-57. PubMed ID: 21707077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and in vivo evaluation of cyclic diaminopropane BACE-1 inhibitors.
    Thompson LA; Shi J; Decicco CP; Tebben AJ; Olson RE; Boy KM; Guernon JM; Good AC; Liauw A; Zheng C; Copeland RA; Combs AP; Trainor GL; Camac DM; Muckelbauer JK; Lentz KA; Grace JE; Burton CR; Toyn JH; Barten DM; Marcinkeviciene J; Meredith JE; Albright CF; Macor JE
    Bioorg Med Chem Lett; 2011 Nov; 21(22):6909-15. PubMed ID: 21974952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of fragment-based NMR screening, X-ray crystallography, structure-based design, and focused chemical library design to identify novel microM leads for the development of nM BACE-1 (beta-site APP cleaving enzyme 1) inhibitors.
    Wang YS; Strickland C; Voigt JH; Kennedy ME; Beyer BM; Senior MM; Smith EM; Nechuta TL; Madison VS; Czarniecki M; McKittrick BA; Stamford AW; Parker EM; Hunter JC; Greenlee WJ; Wyss DF
    J Med Chem; 2010 Feb; 53(3):942-50. PubMed ID: 20043700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, X-ray studies, and biological evaluation of novel BACE1 inhibitors with bicyclic isoxazoline carboxamides as the P3 ligand.
    Ghosh AK; Ghosh K; Brindisi M; Lendy EK; Yen YC; Kumaragurubaran N; Huang X; Tang J; Mesecar AD
    Bioorg Med Chem Lett; 2018 Aug; 28(15):2605-2610. PubMed ID: 29970308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation and biological evaluation of conformationally constrained BACE1 inhibitors.
    Winneroski LL; Schiffler MA; Erickson JA; May PC; Monk SA; Timm DE; Audia JE; Beck JP; Boggs LN; Borders AR; Boyer RD; Brier RA; Hudziak KJ; Klimkowski VJ; Garcia Losada P; Mathes BM; Stout SL; Watson BM; Mergott DJ
    Bioorg Med Chem; 2015 Jul; 23(13):3260-8. PubMed ID: 26001341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2-Substituted-thio-N-(4-substituted-thiazol/1H-imidazol-2-yl)acetamides as BACE1 inhibitors: Synthesis, biological evaluation and docking studies.
    Yan G; Hao L; Niu Y; Huang W; Wang W; Xu F; Liang L; Wang C; Jin H; Xu P
    Eur J Med Chem; 2017 Sep; 137():462-475. PubMed ID: 28624701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
    Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
    J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A stereoselective approach to peptidomimetic BACE1 inhibitors.
    Butini S; Gabellieri E; Brindisi M; Giovani S; Maramai S; Kshirsagar G; Guarino E; Brogi S; La Pietra V; Giustiniano M; Marinelli L; Novellino E; Campiani G; Cappelli A; Gemma S
    Eur J Med Chem; 2013; 70():233-47. PubMed ID: 24158015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 4-Substituted 2-amino-3,4-dihydroquinazolines with a 3-hairpin turn side chain as novel inhibitors of BACE-1.
    Jagtap AD; Kondekar NB; Hung PY; Hsieh CE; Yang CR; Chen GS; Chern JW
    Bioorg Chem; 2020 Jan; 95():103135. PubMed ID: 31923631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis of potent BACE-1 inhibitors incorporating a hydroxyethylene isostere as central core.
    Wångsell F; Gustafsson K; Kvarnström I; Borkakoti N; Edlund M; Jansson K; Lindberg J; Hallberg A; Rosenquist A; Samuelsson B
    Eur J Med Chem; 2010 Mar; 45(3):870-82. PubMed ID: 20036448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 4-Oxo-1,4-dihydro-quinoline-3-carboxamides as BACE-1 inhibitors: synthesis, biological evaluation and docking studies.
    Liu P; Niu Y; Wang C; Sun Q; Zhai Y; Yu J; Sun J; Xu F; Yan G; Huang W; Liang L; Xu P
    Eur J Med Chem; 2014 May; 79():413-21. PubMed ID: 24763262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent BACE-1 inhibitor design using pharmacophore modeling, in silico screening and molecular docking studies.
    John S; Thangapandian S; Sakkiah S; Lee KW
    BMC Bioinformatics; 2011 Feb; 12 Suppl 1(Suppl 1):S28. PubMed ID: 21342558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multipotent AChE and BACE-1 inhibitors for the treatment of Alzheimer's disease: Design, synthesis and bio-analysis of 7-amino-1,4-dihydro-2H-isoquilin-3-one derivates.
    Zhao XJ; Gong DM; Jiang YR; Guo D; Zhu Y; Deng YC
    Eur J Med Chem; 2017 Sep; 138():738-747. PubMed ID: 28728106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure- and property-based design of aminooxazoline xanthenes as selective, orally efficacious, and CNS penetrable BACE inhibitors for the treatment of Alzheimer's disease.
    Huang H; La DS; Cheng AC; Whittington DA; Patel VF; Chen K; Dineen TA; Epstein O; Graceffa R; Hickman D; Kiang YH; Louie S; Luo Y; Wahl RC; Wen PH; Wood S; Fremeau RT
    J Med Chem; 2012 Nov; 55(21):9156-69. PubMed ID: 22928914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2D QSAR studies on series of human beta-secretase (BACE-1) inhibitors.
    Cruz DS; Castilho MS
    Med Chem; 2014 Mar; 10(2):162-73. PubMed ID: 23627297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A physicochemical descriptor based method for effective and rapid screening of dual inhibitors against BACE-1 and GSK-3β as targets for Alzheimer's disease.
    Kumar A; Srivastava G; Sharma A
    Comput Biol Chem; 2017 Dec; 71():1-9. PubMed ID: 28950235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of cyclic acylguanidines as highly potent and selective beta-site amyloid cleaving enzyme (BACE) inhibitors: Part I--inhibitor design and validation.
    Zhu Z; Sun ZY; Ye Y; Voigt J; Strickland C; Smith EM; Cumming J; Wang L; Wong J; Wang YS; Wyss DF; Chen X; Kuvelkar R; Kennedy ME; Favreau L; Parker E; McKittrick BA; Stamford A; Czarniecki M; Greenlee W; Hunter JC
    J Med Chem; 2010 Feb; 53(3):951-65. PubMed ID: 20043696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.